A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

NCT06190093 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration
Age-Related Macular Degeneration
Wet Macular Degeneration

Interventions

BIOLOGICAL: bevacizumab
BIOLOGICAL: ranibizumab

Sponsor

Outlook Therapeutics, Inc.